Breaking News Instant updates and real-time market news.

RETA

Reata Pharmaceuticals

$100.37

4.57 (4.77%)

16:30
10/14/19
10/14
16:30
10/14/19
16:30

Reata Pharmaceuticals trading resumes

RETA Reata Pharmaceuticals
$100.37

4.57 (4.77%)

09/26/19
SBSH
09/26/19
NO CHANGE
SBSH
Buy
Citi opens 'Positive Catalyst Watch' on Reata Pharmaceuticals
Citi analyst Yigal Nochomovitz opened a 90-day "Positive Catalyst Watch" on Reata Pharmaceuticals ahead of the Phase 3 Cardinal data for bardoxolone in Alport syndrome expected in the second half of 2019. The analyst has a "high conviction" in Alport and expects the stock to be up ~50%-75% on positive data. He also expects investors to assign higher probabilities of success for bardoxolone in other rare nephropathies following the positive Alport data. He keeps a Buy rating on Reata shares.
09/26/19
NATL
09/26/19
INITIATION
Target $130
NATL
Buy
Reata Pharmaceuticals initiated with a Buy at National Securities
National Securities analyst Maria Barbera initiated Reata Pharmaceuticals with a Buy and $130 price target.
10/10/19
STFL
10/10/19
NO CHANGE
Target $135
STFL
Buy
Reata Pharmaceuticals 'bold move' should be well received by Street, says Stifel
Stifel analyst Adam Walsh notes that in "a bold move" likely to be well received by the Street, Reata Pharmaceuticals (RETA) reacquired ex-U.S. rights to BARD, OMAV, and other Nrf2 activators from AbbVie (ABBV) for total deal consideration of $330M. Given AbbVie's lack of a significant renal franchise, the reacquisition of ex-U.S. BARD rights restores strategic flexibility to Reata and provides the opportunity to either find a more engaging development partner, go it alone ex-U.S., or sell the company outright, he contends. Further, the analyst believes the deal terms look "highly reasonable" relative to potential ex-U.S. BARD sales. Walsh has a Buy rating and $135 price target on Reata's shares.
10/14/19
LEER
10/14/19
NO CHANGE
Target $180
LEER
Outperform
Reata Pharmaceuticals price target raised to $180 form $139 at SVB Leerink
SVB Leerink analyst Joseph Schwartz raised his price target for Reata Pharmaceuticals to $180 from $139, while reiterating an Outperform rating on the shares. The analyst believes Bardoxolone methyl remains a key growth driver for Reata with Phase.3 CARDINAL data expected near-term. Additional analysis since his CARDINAL preview suggests that a positive CARDINAL outcome has the potential to lift the stock by 25%-50% and that a valuation of $4B-$7B is reasonable post-data. Lastly, although Phase 3 CARDINAL data are expected after American Society of Nephrology Kidney Week, emerging evidence continues to dispel concerns of hyperfiltration, he contends.

TODAY'S FREE FLY STORIES

AEO

American Eagle

$16.01

-0.13 (-0.81%)

16:58
11/12/19
11/12
16:58
11/12/19
16:58
Initiation
American Eagle initiated  »

American Eagle initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OPRT

Oportun Financial

$18.72

0.54 (2.97%)

16:52
11/12/19
11/12
16:52
11/12/19
16:52
Earnings
Oportun Financial sees FY19 EPS $2.16-$2.21, consensus $1.71 »

Sees FY19 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

MUR

Murphy Oil

$24.34

-0.09 (-0.37%)

16:52
11/12/19
11/12
16:52
11/12/19
16:52
Downgrade
Murphy Oil rating change  »

Murphy Oil downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HES

Hess Corp.

$71.79

-1.05 (-1.44%)

16:51
11/12/19
11/12
16:51
11/12/19
16:51
Initiation
Hess Corp. initiated  »

Hess Corp. initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCON

Tracon Pharmaceuticals

$3.46

-0.48 (-12.18%)

16:51
11/12/19
11/12
16:51
11/12/19
16:51
Syndicate
Breaking Syndicate news story on Tracon Pharmaceuticals »

Tracon Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OPRT

Oportun Financial

$18.72

0.54 (2.97%)

16:50
11/12/19
11/12
16:50
11/12/19
16:50
Earnings
Oportun Financial sees Q4 EPS 61c-65c, consensus 62c »

Sees Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

ESTA

Establishment Labs

$23.60

-0.39 (-1.63%)

16:50
11/12/19
11/12
16:50
11/12/19
16:50
Syndicate
Breaking Syndicate news story on Establishment Labs »

Establishment Labs files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 13

    Nov

SE

Sea Limited

$36.78

5.81 (18.76%)

16:49
11/12/19
11/12
16:49
11/12/19
16:49
Syndicate
Breaking Syndicate news story on Sea Limited »

Sea Limited files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

GEVO

Gevo

$2.57

0.065 (2.59%)

16:49
11/12/19
11/12
16:49
11/12/19
16:49
Earnings
Gevo reports Q3 EPS (66c), one estimate (55c) »

Reports Q3 revenue $6.1M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

WMT

Walmart

$119.13

0.1 (0.08%)

16:48
11/12/19
11/12
16:48
11/12/19
16:48
Recommendations
Walmart analyst commentary  »

Baird senses 'upward…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 14

    Nov

LJPC

La Jolla

$6.70

-0.07 (-1.03%)

16:48
11/12/19
11/12
16:48
11/12/19
16:48
Earnings
La Jolla reports Q3 EPS ($1.08), consensus ($1.08) »

Reports Q3 revenue $5.7M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OPRT

Oportun Financial

$18.72

0.54 (2.97%)

16:48
11/12/19
11/12
16:48
11/12/19
16:48
Earnings
Oportun Financial reports Q3 EPS 64c, consensus 44c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

FCPT

Four Corners Property Trust

$26.95

-0.16 (-0.59%)

16:48
11/12/19
11/12
16:48
11/12/19
16:48
Syndicate
Breaking Syndicate news story on Four Corners Property Trust »

Four Corners Property…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$362.89

-4.08 (-1.11%)

16:47
11/12/19
11/12
16:47
11/12/19
16:47
Hot Stocks
Boeing names Conrad Chun VP of Communications for Boeing Commercial Airplanes »

Boeing announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

ADPT

Adaptive Biotechnologies

$28.35

0.01 (0.04%)

16:46
11/12/19
11/12
16:46
11/12/19
16:46
Earnings
Adaptive Biotechnologies reports Q3 EPS (11c), consensus (24c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 07

    Dec

CALA

Calithera Biosciences

$3.15

0.01 (0.32%)

16:46
11/12/19
11/12
16:46
11/12/19
16:46
Earnings
Calithera Biosciences reports Q3 EPS (38c), consensus (45c) »

Cash, cash equivalents…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

HII

Huntington Ingalls

$253.94

2.975 (1.19%)

16:46
11/12/19
11/12
16:46
11/12/19
16:46
Hot Stocks
Huntington Ingalls starts fabribation of legend-class cutter Calhoun »

Huntington Ingalls…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SDC

SmileDirectClub

$11.02

-0.83 (-7.00%)

16:45
11/12/19
11/12
16:45
11/12/19
16:45
Hot Stocks
SmileDirectClub reports Q3 unique aligner shipments of 106,070 »

SmileDirectClub reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

SDC

SmileDirectClub

$11.02

-0.83 (-7.00%)

16:44
11/12/19
11/12
16:44
11/12/19
16:44
Hot Stocks
Breaking Hot Stocks news story on SmileDirectClub »

SmileDirectClub shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

CDLX

Cardlytics

$39.85

0.17 (0.43%)

16:44
11/12/19
11/12
16:44
11/12/19
16:44
Earnings
Cardlytics raises FY19 revenue view to $196M-$200M from $180M-$190M 

Consensus $190.49M.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 09

    Dec

RNG

RingCentral

$172.89

2.57 (1.51%)

, AVYA

Avaya

$12.53

0.08 (0.64%)

16:43
11/12/19
11/12
16:43
11/12/19
16:43
Hot Stocks
RingCentral issues 2.17M Class A shares to Avaya »

RingCentral, Inc. (RNG)…

RNG

RingCentral

$172.89

2.57 (1.51%)

AVYA

Avaya

$12.53

0.08 (0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 13

    Nov

  • 13

    Nov

  • 09

    Dec

SSTI

ShotSpotter

$20.35

-0.01 (-0.05%)

16:43
11/12/19
11/12
16:43
11/12/19
16:43
Earnings
ShotSpotter guides initial FY20 revenue $48M-$50M, consensus $55.94M »

Management also expects…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

SDC

SmileDirectClub

$11.02

-0.83 (-7.00%)

16:43
11/12/19
11/12
16:43
11/12/19
16:43
Hot Stocks
SmileDirectClub targets long-term marketing, selling expenses 40%-45% of sales »

SmileDirectClub said in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

SSTI

ShotSpotter

$20.35

-0.01 (-0.05%)

16:43
11/12/19
11/12
16:43
11/12/19
16:43
Earnings
ShotSpotter cuts FY19 revenue view to $40M-$40.5M from $42M-$44.5M 

Consensus $42.9M.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

CDLX

Cardlytics

$39.85

0.17 (0.43%)

16:43
11/12/19
11/12
16:43
11/12/19
16:43
Earnings
Breaking Earnings news story on Cardlytics »

Cardlytics sees Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 09

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.